Mereo BioPharma Group (MREO) Short Interest Ratio & Short Volume $2.19 +0.01 (+0.46%) Closing price 05/28/2025 04:00 PM EasternExtended Trading$2.22 +0.04 (+1.60%) As of 05/28/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Mereo BioPharma Group Short Interest DataMereo BioPharma Group (MREO) has a short interest of 7.95 million shares, representing 5.34% of the float (the number of shares available for trading by the public). This marks a 4.47% increase in short interest from the previous month. The short interest ratio (days to cover) is 5.4, indicating that it would take 5.4 days of the average trading volume of 1.11 million shares to cover all short positions.Current Short Interest7,950,000 sharesPrevious Short Interest7,610,000 sharesChange Vs. Previous Month+4.47%Dollar Volume Sold Short$17.33 millionShort Interest Ratio5.4 Days to CoverLast Record DateMay 15, 2025Outstanding Shares159,000,000 sharesShort Percent of Float5.34%Today's Trading Volume713,980 sharesAverage Trading Volume1,110,847 sharesToday's Volume Vs. Average64% Short Selling Mereo BioPharma Group? Sign up to receive the latest short interest report for Mereo BioPharma Group and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartMREO Short Interest Over TimeMREO Days to Cover Over TimeMREO Percentage of Float Shorted Over Time Mereo BioPharma Group Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/20257,950,000 shares $17.33 million +4.5%5.3%5.4 $2.18 4/30/20257,610,000 shares $19.71 million +15.3%N/A5.2 $2.59 4/15/20256,600,000 shares $13.20 million +0.9%4.4%4.6 $2.00 3/31/20256,540,000 shares $14.72 million +8.5%4.4%4.8 $2.25 3/15/20256,030,000 shares $15.80 million -5.2%4.1%5 $2.62 2/28/20256,360,000 shares $15.26 million -12.4%4.3%5.2 $2.40 2/15/20257,260,000 shares $20.84 million +6.5%4.9%6.7 $2.87 1/31/20256,820,000 shares $20.53 million -5.3%N/A6.6 $3.01 1/15/20257,200,000 shares $21.82 million -10.3%N/A7.2 $3.03 12/31/20248,030,000 shares $28.11 million +13.9%N/A9.9 $3.50 Get the Latest News and Ratings for MREO and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Mereo BioPharma Group and its competitors with MarketBeat's FREE daily newsletter. 12/15/20247,050,000 shares $26.37 million +6.3%N/A9 $3.74 11/30/20246,630,000 shares $23.90 million +17.8%N/A8.8 $3.61 11/15/20245,630,000 shares $19.87 million +23.2%N/A7.5 $3.53 10/31/20244,570,000 shares $19.24 million -11.4%N/A6.1 $4.21 10/15/20245,160,000 shares $23.43 million +5.7%N/A6.1 $4.54 9/30/20244,880,000 shares $20.06 million +7.5%N/A5.5 $4.11 9/15/20244,540,000 shares $19.43 million +0.9%N/A4.8 $4.28 8/31/20244,500,000 shares $21.11 million -0.9%N/A4 $4.69 8/15/20244,540,000 shares $18.52 million +3.9%N/A3.8 $4.08 7/31/20244,370,000 shares $17.74 million +40.1%N/A4 $4.06 7/15/20243,120,000 shares $12.95 million +6.9%N/A2.9 $4.15 6/30/20242,920,000 shares $10.51 million +24.3%N/A2.7 $3.60 6/15/20242,350,000 shares $9.99 million -2.1%N/A2.1 $4.25 5/31/20242,400,000 shares $8.28 million +8.6%N/A2.6 $3.45 5/15/20242,210,000 shares $7.01 million -21.9%N/A2.2 $3.17 4/30/20242,830,000 shares $8.63 million +2.2%N/A2.4 $3.05 4/15/20242,770,000 shares $7.40 million +18.9%N/A1.8 $2.67 3/31/20242,330,000 shares $7.69 million +6.4%N/A1.3 $3.30 3/15/20242,190,000 shares $6.81 million -1.8%N/A1.3 $3.11 2/29/20242,230,000 shares $8.47 million -19.8%N/A1.4 $3.80 2/15/20242,780,000 shares $10.26 million +25.8%N/A1.8 $3.69 1/31/20242,210,000 shares $8.38 million +59.0%N/A1.5 $3.79 1/15/20241,390,000 shares $4.10 million -6.1%N/A1.1 $2.95 12/31/20231,480,000 shares $3.42 million -18.2%N/A1.1 $2.31 12/15/20231,810,000 shares $3.71 million -33.9%N/A1.4 $2.05 11/30/20232,740,000 shares $5.73 million -3.5%N/A2.2 $2.09 11/15/20232,840,000 shares $6.25 million -20.9%N/A2.3 $2.20 10/31/20233,590,000 shares $7.20 million +13.6%N/A2.9 $2.01 10/15/20233,160,000 shares $4.08 million +4.6%N/A2.6 $1.29 9/30/20233,020,000 shares $3.90 million -15.2%N/A3.5 $1.29Shocking AI play that’s beats Nvidia by a country mile (Ad)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 9/15/20233,560,000 shares $5.55 million -26.6%N/A3.9 $1.56 8/31/20234,850,000 shares $6.64 million -19.0%N/A4.4 $1.37 8/15/20235,990,000 shares $7.55 million -3.4%N/A3.7 $1.26 7/31/20236,200,000 shares $8.25 million -19.5%N/A3.4 $1.33 7/15/20237,700,000 shares $9.63 million -26.9%N/A3.8 $1.25 6/30/202310,530,000 shares $13.90 million +11.2%N/A5.3 $1.32 6/15/20239,470,000 shares $13.54 million +14.8%N/A4.8 $1.43 5/31/20238,250,000 shares $8.33 million +59.9%N/A4.5 $1.01 5/15/20235,160,000 shares $6.45 million +22.0%N/A3.8 $1.25 4/30/20234,230,000 shares $5.54 million +8.5%N/A3.6 $1.31 4/15/20233,900,000 shares $4.10 million +2.4%N/A3.9 $1.05 3/31/20233,810,000 shares $2.69 million -0.5%N/A4.3 $0.71 3/15/20233,830,000 shares $3.26 million +15.4%N/A4.2 $0.85 2/28/20233,320,000 shares $2.96 million -16.4%N/A3.8 $0.89 2/15/20233,970,000 shares $4.41 million +12.2%N/A4.4 $1.11 1/31/20233,540,000 shares $3.31 million -4.6%N/A4.9 $0.94 1/15/20233,710,000 shares $3.29 million +6.3%N/A5.5 $0.89 12/30/20223,490,000 shares $2.62 million -27.4%N/A5.9 $0.75 12/15/20224,810,000 shares $3.67 million -3.0%N/A9.4 $0.76 11/30/20224,960,000 shares $3.91 million -2.8%N/A11.5 $0.79 11/15/20225,100,000 shares $4.04 million -10.7%N/A11 $0.79 10/31/20225,710,000 shares $5.71 million -6.2%N/A8.8 $1.00 10/15/20226,090,000 shares $6.09 million -5.3%N/A7.7 $1.00 9/30/20226,430,000 shares $5.54 million -4.7%N/A5.8 $0.86 9/15/20226,750,000 shares $7.22 million -3.9%N/A3.9 $1.07 8/31/20227,020,000 shares $8.42 million +11.3%6.5%1.4 $1.20 8/15/20226,310,000 shares $8.20 million +31.5%5.9%1.2 $1.30 7/31/20224,800,000 shares $5.81 million -7.9%4.7%0.9 $1.21 7/15/20225,210,000 shares $9.01 million -11.5%5.1%1 $1.73 6/30/20225,890,000 shares $6.60 million +65.5%5.7%1.2 $1.12 6/15/20223,560,000 shares $2.46 million -13.2%3.5%0.8 $0.69 5/31/20224,100,000 shares $2.07 million -24.8%4.0%3.9 $0.51 5/15/20225,450,000 shares $2.13 million -20.4%5.3%5.6 $0.39 4/30/20226,850,000 shares $4.25 million -2.1%N/A9.8 $0.62 4/15/20227,000,000 shares $6.41 million -0.9%N/A13.2 $0.92 3/31/20227,060,000 shares $7.91 million -1.0%N/A13.6 $1.12 3/15/20227,130,000 shares $9.27 million +7.1%N/A13 $1.30 2/28/20226,660,000 shares $8.26 million -9.8%N/A10.4 $1.24 2/15/20227,380,000 shares $10.04 million No ChangeN/A9.9 $1.36 1/31/20227,380,000 shares $9.67 million +3.7%8.0%8.8 $1.31 1/15/20227,120,000 shares $10.18 million +10.7%7.7%8 $1.43 12/31/20216,430,000 shares $10.29 million +17.6%7.6%7.4 $1.60 12/15/20215,470,000 shares $8.97 million +4.4%6.5%6 $1.64 11/30/20215,240,000 shares $9.22 million -48.0%6.2%5.9 $1.76 11/15/202110,080,000 shares $22.48 million +20.4%12.0%12.6 $2.23 10/29/20218,370,000 shares $18.83 million -3.8%8.4%10.1 $2.25 10/15/20218,700,000 shares $18.97 million +20.3%8.7%10.2 $2.18 9/30/20217,230,000 shares $17.50 million -3.9%7.2%7.2 $2.42 9/15/20217,520,000 shares $19.33 million -2.3%7.5%6.7 $2.57 8/31/20217,700,000 shares $21.48 million -2.3%7.7%5.7 $2.79Shocking AI play that’s beats Nvidia by a country mile (Ad)You’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is about to announce could change the AI market once again. Experts already predict the total addressable market could climb past $20 trillion. But Sykes believes most investors have missed what’s coming next. He’s tracking a new shift — and says the biggest gains are still ahead.Click to find out what Nvidia’s CEO might reveal… and how Sykes is preparing to ride the wave. 8/13/20217,880,000 shares $17.73 million -0.4%7.9%5.5 $2.25 7/30/20217,910,000 shares $20.33 million +4.4%8.0%5.6 $2.57 7/15/20217,580,000 shares $21.30 million -32.1%7.3%5.4 $2.81 6/30/202111,160,000 shares $35.38 million +56.3%10.8%8.1 $3.17 6/15/20217,140,000 shares $23.06 million -17.8%6.9%4.5 $3.23 5/28/20218,690,000 shares $28.42 million +5.9%8.4%5.8 $3.27 5/14/20218,210,000 shares $24.47 million +0.5%N/A4.4 $2.98 4/30/20218,170,000 shares $29.49 million -15.3%N/A3.1 $3.61 4/15/20219,640,000 shares $33.35 million +17.3%N/A3.7 $3.46 3/31/20218,220,000 shares $27.45 million +71.3%N/A3.2 $3.34 3/15/20214,800,000 shares $19.58 million +27.3%N/A1.3 $4.08 2/26/20213,770,000 shares $15.08 million -55.9%N/A1.1 $4.00 2/12/20218,550,000 shares $29.07 million +21.1%N/A2.8 $3.40 1/29/20217,060,000 shares $18.36 million +7.5%N/A3.3 $2.60 1/15/20216,570,000 shares $22.01 million +16.1%N/A3.2 $3.35 12/31/20205,660,000 shares $20.09 million +249.4%N/A2.9 $3.55 12/15/20201,620,000 shares $3.26 million +33.9%N/A0.9 $2.01 11/30/20201,210,000 shares $2.95 million -1.6%N/A5.5 $2.44 11/15/20201,230,000 shares $2.85 million -0.8%N/A6.8 $2.32 10/30/20201,240,000 shares $2.99 million +14.8%N/A5.9 $2.41 10/15/20201,080,000 shares $2.48 million +14.1%N/A4.4 $2.30 9/30/2020946,300 shares $2.48 million -0.5%N/A3.9 $2.62 9/15/2020951,300 shares $2.80 million +16.6%N/A4 $2.94 8/31/2020815,700 shares $2.44 million +93.1%N/A2.8 $2.99 8/14/2020422,400 shares $1.20 million -4.2%N/A1.1 $2.83 7/31/2020440,700 shares $1.26 million -1.6%N/A1.3 $2.85 7/15/2020447,700 shares $1.34 million +3.0%N/A1.4 $2.99 6/30/2020434,500 shares $1.28 million +94.8%1.9%1.4 $2.94 6/15/2020223,100 shares $624,680.00 +2,200.0%N/A0.8 $2.80 5/29/20209,700 shares $12,125.00 +56.5%N/A0 $1.25 MREO Short Interest - Frequently Asked Questions What is Mereo BioPharma Group's current short interest? Short interest is the volume of Mereo BioPharma Group shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 7,950,000 shares of MREO short. 5.34% of Mereo BioPharma Group's shares are currently sold short. Learn More on Mereo BioPharma Group's current short interest. What is a good short interest ratio for Mereo BioPharma Group? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. MREO shares currently have a short interest ratio of 5.0. Learn More on Mereo BioPharma Group's short interest ratio. Which institutional investors are shorting Mereo BioPharma Group? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Mereo BioPharma Group: Jane Street Group LLC, Persistent Asset Partners Ltd, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Mereo BioPharma Group? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.34% of Mereo BioPharma Group's floating shares are currently sold short. Is Mereo BioPharma Group's short interest increasing or decreasing? Mereo BioPharma Group saw a increase in short interest in May. As of May 15th, there was short interest totaling 7,950,000 shares, an increase of 4.5% from the previous total of 7,610,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Mereo BioPharma Group's short interest compare to its competitors? 5.34% of Mereo BioPharma Group's shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Mereo BioPharma Group: Structure Therapeutics Inc. (17.04%), Janux Therapeutics, Inc. (23.30%), Evotec SE (0.24%), ARS Pharmaceuticals, Inc. (33.28%), Adaptive Biotechnologies Co. (6.57%), Vera Therapeutics, Inc. (14.71%), Dyne Therapeutics, Inc. (28.77%), ANI Pharmaceuticals, Inc. (10.13%), Ocular Therapeutix, Inc. (9.12%), Amphastar Pharmaceuticals, Inc. (11.52%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Mereo BioPharma Group stock? Short selling MREO is an investing strategy that aims to generate trading profit from Mereo BioPharma Group as its price is falling. MREO shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Mereo BioPharma Group? A short squeeze for Mereo BioPharma Group occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of MREO, which in turn drives the price of the stock up even further. How often is Mereo BioPharma Group's short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including MREO, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies Structure Therapeutics Short Squeeze Janux Therapeutics Short Squeeze Evotec Short Squeeze ARS Pharmaceuticals Short Squeeze Adaptive Biotechnologies Short Squeeze Vera Therapeutics Short Squeeze Dyne Therapeutics Short Squeeze ANI Pharmaceuticals Short Squeeze Ocular Therapeutix Short Squeeze Amphastar Pharmaceuticals Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:MREO) was last updated on 5/29/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mereo BioPharma Group plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Mereo BioPharma Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MREO Stock Free MREO Stock Alerts